Dynasty Wealth Management LLC Buys Shares of 8,327 Cencora, Inc. (NYSE:COR)

Dynasty Wealth Management LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 8,327 shares of the company’s stock, valued at approximately $1,871,000.

Other hedge funds have also recently made changes to their positions in the company. JFS Wealth Advisors LLC grew its position in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC lifted its stake in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares in the last quarter. Kentucky Trust Co purchased a new stake in shares of Cencora during the fourth quarter valued at approximately $33,000. WASHINGTON TRUST Co increased its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora in the 3rd quarter worth approximately $41,000. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

NYSE:COR opened at $248.71 on Friday. The company has a 50 day moving average price of $240.74 and a 200 day moving average price of $237.66. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $48.23 billion, a P/E ratio of 35.38, a PEG ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Ratings Changes

Several analysts recently commented on the company. Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Barclays raised their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.